Aflibercept injection
Products billed under this code include Eylea.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Eylea.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Eylea | Regeneron Pharmaceuticals, Inc. | 61755-0005-01 | 2 | $1,444.502 |
| Eylea | Regeneron Pharmaceuticals, Inc. | 61755-0005-02 | 2 | $1,444.502 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $722.251 | −$21.354 | 1 MG | Aflibercept injection | v1, posted September 17, 2026 |
| 3Q26 | $743.605 | +$11.72 | 1 MG | Aflibercept injection | v1, posted September 15, 2026 |
| 2Q26 | $731.885 | −$32.016 | 1 MG | Aflibercept injection | v1, posted September 15, 2026 |
| 1Q26 | $763.901 | −$7.657 | 1 MG | Aflibercept injection | v1, posted September 15, 2026 |
| 4Q25 | $771.558 | −$18.479 | 1 MG | Aflibercept injection | v1, posted September 8, 2026 |
| 3Q25 | $790.037 | −$5.824 | 1 MG | Aflibercept injection | v1, posted March 10, 2026 |
| 2Q25 | $795.861 | −$5.204 | 1 MG | Aflibercept injection | v1, posted March 10, 2026 |
| 1Q25 | $801.065 | −$20.915 | 1 MG | Aflibercept injection | v1, posted December 19, 2025 |
| 4Q24 | $821.98 | −$13.419 | 1 MG | Aflibercept injection | v1, posted June 11, 2025 |
| 3Q24 | $835.399 | −$5.729 | 1 MG | Aflibercept injection | v1, posted June 11, 2025 |
| 2Q24 | $841.128 | −$21.152 | 1 MG | Aflibercept injection | v1, posted March 11, 2025 |
| 1Q24 | $862.28 | −$5.961 | 1 MG | Aflibercept injection | v1, posted December 19, 2024 |
| 4Q23 | $868.241 | −$7.429 | 1 MG | Aflibercept injection | v1, posted October 10, 2024 |
| 3Q23 | $875.67 | −$17.881 | 1 MG | Aflibercept injection | v1, posted June 5, 2024 |
| 2Q23 | $893.551 | −$4.776 | 1 MG | Aflibercept injection | v1, posted February 23, 2024 |
| 1Q23 | $898.327 | −$4.67 | 1 MG | Aflibercept injection | v1, posted December 6, 2023 |
| 4Q22 | $902.997 | −$9.892 | 1 MG | Aflibercept injection | v1, posted June 22, 2023 |
| 3Q22 | $912.889 | −$1.311 | 1 MG | Aflibercept injection | v1, posted June 9, 2023 |
| 2Q22 | $914.20 | −$1.547 | 1 MG | Aflibercept injection | v1, posted December 14, 2022 |
| 1Q22 | $915.747 | −$2.196 | 1 MG | Aflibercept injection | v1, posted June 8, 2022 |
| 4Q21 | $917.943 | +$1.534 | 1 MG | Aflibercept injection | v1, posted June 2, 2022 |
| 3Q21 | $916.409 | −$2.459 | 1 MG | Aflibercept injection | v1, posted June 2, 2022 |
| 2Q21 | $918.868 | −$2.887 | 1 MG | Aflibercept injection | v1, posted March 1, 2022 |
| 1Q21 | $921.755 | – | 1 MG | Aflibercept injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.